Functional Evaluation and Characterization of a Newly Developed Silicone Oil-Free Prefillable Syringe System

KEISUKE YOSHINO,1 KOJI NAKAMURA,1 ARISA YAMASHITA,2 YOSHIIKO ABE,1 KAZUHIRO IWASAKI,1 YUKIE KANAZAWA,2 KAORI FUNATSU,1 TSUYOSHI YOSHIMOTO,2 SHIGERU SUZUKI1

1Terumo Corporation, R&D Center, Nakai-machi, Ashigarakami-gun, Kanagawa 259-0151, Japan
2Terumo Corporation, Fujinomiya Factory, Fujinomiya-shi, Shizuoka 418-0004, Japan

Received 20 November 2013; revised 19 February 2014; accepted 20 February 2014
Published online 18 March 2014 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.23945

ABSTRACT: The functionality of a newly developed silicone oil-free (SOF) syringe system, of which the plunger stopper is coated by a novel coating technology (i-coatingTM), was assessed. By scanning electron microscopy observations and other analysis, it was confirmed that the plunger stopper surface was uniformly covered with the designed chemical composition. A microflow imaging analysis showed that the SOF system drastically reduced both silicone oil (SO) doplets and oil-induced aggregations in a model protein formulation, whereas a large number of subvisible particles and protein aggregations were formed when a SO system was used. Satisfactory container closure integrity (CCI) was confirmed by means of dye and microorganism penetration studies. Furthermore, no significant difference between the break loose and gliding forces was observed in the former, and stability studies revealed that the SOF system could perfectly show the integrity (CCI) was confirmed by means of dye and microorganism penetration studies. Furthermore, no significant difference between the break loose and gliding forces was observed in the former, and stability studies revealed that the SOF system could perfectly show the integrity. In particular, no risk of SO-induced aggregation can bring additional value in the highly sensitive biotech drug market.

INTRODUCTION

The recently increased interest in prefilled syringes (PFS) is largely driven by many advantages against traditional ampoules and vials, such as allowing quick and accurate dosing, minimizing dosing errors, reducing the risk of biological contamination, enhanced convenience and ease of use, preventing of overfill, and so on. On increasing number of available biological drugs, the demand for the use of PFS has considerably increased in recent years.

Silicone oil (SO) is widely used as a lubricant in syringes to ensure a smooth gliding behavior of the plunger inside the barrel. Furthermore, siliconization effectively prevents the plunger stoppers from sticking together during the material shipping and manufacturing process. It is also important to minimize the mechanical force when the plunger stoppers are inserted into a barrel using a mechanical stoppering machine. Siliconization is therefore essential to the process capability of the SO-lubricated syringe. However, it is known that the use of SO-coated syringes leads to difficulties in case of some silicone-sensitive drugs, such as protein-based drugs. For example, several reports in the 1980s implicated that the ingress of SO from disposable syringes caused aggregation of human insulin.1–5 Researchers continue to seek how SO can accelerate the intermolecular interactions of proteins, and stability studies revealed that the oil could negatively affect the chemical and physical stability of the protein formulation, thereby causing a loss of soluble proteins.6,7 Additional works have been performed to assess the effects of ionic strength and the type of surfactants that can be used to minimize the risk of a SO-induced aggregation.8–10

Silicone oil-induced aggregation has now become one of the most frequently discussed subjects in the field of PFS, particularly for developers of highly sensitive biotech drugs.6,11,12 Once SO detaches from the inner wall of the barrel, oil droplets are formed that contribute to the population of subvisible particles. The levels of visible and subvisible particles have become critical also to the quality of drug products in PFS.13–15 To mitigate the risk, the reduction of the SO quantity may be one of the options to be considered, but this may not be adequate because siliconization is essential to ensure the functionality of the syringe over the shelf life of the product, and even if the quantity of SO is reduced, the risk of SO-induced aggregation cannot be eliminated completely.

Under such circumstances described above, the demand for the SO-free (SOF) system has been rising, and various technologies have been proposed so far.16 Most of them are coating technologies in which the surface of the barrel and/or plunger stopper is coated with a lubricious, compatible, and physicochemically inert material. In response to this unmet need, Terumo created an innovative coating technology, which resulted in the successful introduction of an SOF system for polymer-based PFS in 2005 within the Japanese market that is still supplied in the market today.

Through continued research and development, Terumo has introduced the next generation of SOF coating technology called i-coatingTM for use on plunger stoppers. By using this
technology, novel SOF system for prefilleable syringes can be accomplished.

The purpose of the present study is to characterize the functionality of this novel SOF system by comparing it with current SO system. In this paper, the coated surface was characterized by means of scanning electron microscopic (SEM) observations, FTIR analysis, and X-ray photoelectron spectroscopy (XPS), and the influences on the generation of subvisible particles, container closure integrity (CCI), and break loose gliding forces as important attributes of PFS were assessed.

**MATERIALS AND METHODS**

**Materials**

PLAJEX™ syringe [Polymer based prefilleable syringe, 1 mL long staked needle (27G)] (SOF syringe system) was provided by Terumo Corporation (Tokyo, Japan), which is a newly developed prefilleable syringe with a polymer barrel made of cyclic olefin polymer and a butyl rubber plunger stopper coated by use of the i-coating™ technology (a proprietary coating). The corresponding PLAJEX™ syringe lubricated by SO with an uncoated plunger stopper (SO system for comparison) was also provided by Terumo Corporation. A butyl rubber sheet of 1 mm in thickness was obtained from Asahi Rubber Inc. (Saitama, Japan). Using the i-coating™ technology, the coated butyl rubber sheet was provided by Terumo Corporation. As a reference sample, SO-coated butyl rubber sheet was also provided by Terumo Corporation. L-Asparaginase (Asp) was purchased from Prospec-Tany TechnoGene Ltd. (Rehovot, Israel); human IgG was purchased from Equitech-Bio Inc. (Kerrville, Texas, USA); albumin from bovine serum (BSA) and lysozyme from chicken egg white (Lyso) were purchased from Sigma–Aldrich Company LLC., (St. Louis, MO, USA), respectively. Triptic soy agar and triptic soy broth (TSB) were purchased from Becton, Dickenson and Company (Franklin lakes, NJ, USA). Isotonic sodium chloride solution and commercially available saline solution of Japanese Pharmacopoeia grade (JP grade) were obtained from Terumo Corporation. Water for injection (20 mL) was JP grade and purchased from Osaka Pharmaceutical Company Ltd., (Tokyo, Japan). Crystal violet and all buffer salts (sodium phosphate monobasic, sodium phosphate dibasic, and sodium chloride) were purchased from Kanto Chemical Corporation (Tokyo, Japan). All other chemicals and reagents were of analytical grade.

**Scanning Electron Microscopy**

Scanning electron microscopic observations were performed using a microscope model KEYENCE VE8800 (Tokyo, Japan) to assess the integrity of the coating layer of the plunger stopper. The surface and the cross-section of the coated and uncoated plunger stoppers were observed with magnifications of ×300 or ×1000. To produce a cross-section, a sample was cut vertically by a razor. After platinum was sputtered, the top surfaces and cross-sections of the samples were observed at an acceleration voltage of 1.7 kV.

**Fourier Transform-Infrared Spectroscopy**

The top surface of the uncoated and coated plunger stopper was analyzed using an FTIR spectrometer (Spectrum100; PerkinElmer, Wellesley, Massachusetts) equipped with a universal attenuated total reflectance (ATR) sampling accessory. ATR–FTIR spectra were recorded at a resolution of 4 cm⁻¹ and 16 scans per specimen were averaged in a wavenumber range from 650 to 4000 cm⁻¹.

**X-Ray Photoelectron Spectroscopy**

The top surface of the coated plunger stopper was analyzed by means of XPS (Axis-NOVA, Kratos, Manchester, UK) using monochromated Al-Kα (1486.6 eV) X-ray radiation. The X-ray tube was operated at 15 kV and 20 mA. The take-off angle between the sample plane and the axis of the analyzer was 90°. A pass energy of 80 eV was chosen for the acquisition of a survey spectrum (0–1000 eV). The pressure was maintained below 10⁻⁸ Pa during the measurements.

**Protein Aggregation Study**

Ten thousand units of Asp were dissolved in 2 mL of water for injection (JP grade). After complete dissolution, the syringes were filled with 1.0 mL of the Asp solution and stopped with plunger stoppers leaving a predetermined headspace of 0.4 mL. The syringes were also filled with 1.0 mL of pure water for injection as reference for the protein aggregation study. After filling, the syringes were shaken in a shaker (SR-I; TAITEC Company Ltd., Saitama, Japan) for 30 min at 250 rpm at room temperature. Immediately after shaking, aliquots of the sample solution were drawn out through a needle by actuation of the plunger stopper and analyzed for particle concentration by micro-flow imaging (MFI). DPA4200 (Brightwell Technologies Inc., Ottawa, Canada) was used for the measurement of subvisible particles. The number of subvisible particles whose equivalent circular diameter is larger than 5 μm was analyzed in this study. Moreover, to obtain information about particle shape, an aspect ratio (AR) filter was employed to distinguish circular (AR ≥ 0.85) and noncircular particles (AR < 0.85). Here, particles having AR ≥ 0.85 and AR < 0.85 are regarded as SO droplets and SO-induced protein aggregates, respectively, according to previous studies. In addition, IgG, BSA, and Lyso were dissolved at 1 mg/mL in a buffer (10 mM Na₂HPO₄, 130 mM NaCl, pH 7.2) and used. Subvisible particles of these protein solutions were also measured in the same manner as described above.

**Dye Penetration Study**

To assess the CCI of the syringes, a dye penetration study was conducted. One milliliter of water was filled into the syringes and the headspace of the syringes was adjusted to predetermined distances (0.5, 0.75, 1.0, and 1.35 mm) by pushing the plunger stopper down. A small amount (0.15 mL) of 1% crystal violet aqueous solution was then placed into the space between the plunger stopper and the flange. The sample syringes were vertically placed in a decompressed chamber (adjusted at −19.6 kPa with respect to normal atmospheric pressure). After 2 h, the water in the syringes was carefully drawn out through a needle and photometrically analyzed to determine the dye concentration using a spectrophotometer SHIMADZU UV-2450 (Kyoto, Japan).

**Microorganism Penetration Study**

The study was performed according to the method proposed by the pharmaceutical inspection convention. In addition to the intact PLAJEX™ syringe, a PLAJEX™ syringe with a pinhole (size of about 8 μm) on the pathway of the barrel was
used as a positive control. All the syringe samples were steriliz-
ed in an autoclave. The TSB culture medium was filled into
the sterilized syringes by aseptic manipulation. All the sam-
ple samples were cultured at 31 ± 1°C for 7 days. After confir-
mation of sterility, they were immersed into a bacterial broth (10⁶
 cfu/mL) in a pressurized chamber (+0.02 MPa above normal
atmospheric pressure) for 30 min and, then, were taken and
the barrel surfaces were washed by water for injection and
70% ethanol. The pinhole of the positive control was closed by
glue. After that, the samples were incubated at 31 ± 1°C for 14
days. The occurrence of microbial growth was judged by visual
observation.

Dynamic Friction Coefficient Study

The dynamic friction coefficient was analyzed using a
continuous-loading surface property tester (TRIBOGEAR;
Shinto Scientific Company Ltd., Tokyo, Japan). A steel ball
with 10 mm in diameter was put on the surface of the sam-
plesheet (40 × 40 mm² in size) and rolled on the surface along
distance of 20 mm at a speed of 3.0 mm/s at room temperature
to measure the dynamic friction coefficient. In accordance with
previous studies, the amount of SO on the sheet was adjusted
such that it was equivalent to the amount that is realistically
present in a prefilled syringe (0.7 mg/syringe).16,20,21

Gliding Force Measurement

Gliding forces were measured using a universal testing ma-
chine (EZtest; SHIMADZU corporation, Kyoto, Japan). Each

RESULTS AND DISCUSSION

SEM Observation

The plunger stoppers coated by i-coating™ were observed by
SEM to verify the integrity of the coating. The surface and
cross-sectional images of uncoated plunger stoppers were rela-
tively rough (Figs. 1a and 1b), whereas a quite smooth surface
was observed in case of the coated plunger stopper (Fig. 1c).
In addition, as shown in Figure 1d, the coated layer was quite
uniform with a thickness of about 5–10 µm. By this SEM obser-
vation, it was confirmed that plunger stoppers provided with
the SOF system are uniformly coated without any defects by
means of i-coating™.

Figure 1.  SEM micrographs of the surface and cross-section of the plunger stoppers coated by i-coating™. (a) Top surface of an uncoated
plunger stopper (×300), (b) cross-section of an uncoated plunger stopper (×1000), (c) top surface of a coated plunger stopper (×300), and (d)
cross-section of a coated plunger stopper (×1000).

Yoshino et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:1520–1528, 2014 DOI 10.1002/jps.23945
Figure 2. FTIR spectrum of (a) the surface of the coated plunger stopper, (b) reference spectrum of silicone, and (c) the surface of the uncoated plunger stopper. The peaks between (a) and (b) at 2962 cm\(^{-1}\) (methyl CH), 1260 cm\(^{-1}\) (Si–CH\(_3\)), 1089 cm\(^{-1}\) (Si–O–Si), 1013 cm\(^{-1}\) (Si–C), and 799 cm\(^{-1}\) [Si–(CH\(_3\))\(_2\)] coincided well with those of the reference spectrum. (d) XPS survey spectrum, measured at the top surface of the coated plunger stopper.

FTIR and XPS Analysis

Figure 2a shows a FTIR spectrum of the surface of a coated plunger stopper. The peaks observed around 2962 cm\(^{-1}\) (methyl CH), 1260 cm\(^{-1}\) (Si–CH\(_3\)), 1089 cm\(^{-1}\) (Si–O–Si), 1013 cm\(^{-1}\) (Si–C), and 799 cm\(^{-1}\) [Si–(CH\(_3\))\(_2\)] well coincided with those of the FTIR reference spectrum (Fig. 2b), clearly indicating that the surface layer of the plunger stopper was formed by the silicone-based resin, as intended. As a control, Figure 2c shows the FTIR spectrum of the surface of an uncoated plunger stopper. As seen in Figure 2c, butyl rubber-related peaks were observed around 1472 cm\(^{-1}\) (CH\(_2\), CH\(_3\)), 1390 cm\(^{-1}\) (tert-butyl CC), and 1366 cm\(^{-1}\) (tert-butyl CH). In contrast, these distinctive peaks were not observed in Figure 2a. This FTIR spectra comparison also helped confirm that the plunger stoppers equipped in the SOF system were uniformly coated by silicone-based resin employing the i-coating\(^\text{TM}\) technology.

Protein Aggregation

A comparative study was conducted to assess the difference in protein aggregation between the SO and the SOF system by means of a MFI technique, according to previous studies\(^{20,21}\). In this study, Asp aqueous solution (Asp sol.), IgG aqueous solution (IgG sol.), BSA aqueous solution (BSA sol.), and Lyso aqueous solution (Lyso sol.) were used as silicone-sensitive model protein solutions, and the sample syringes were placed under shaking condition. Another set of syringes was filled with water for injection (JP) as reference. The number of particles with different shape (AR \(\geq 0.85\)) and (AR \(< 0.85\)) are compared in Figures 3a and 3b, respectively. As seen in Figure 3a, in case of water-filled syringes, a remarkable number of circularly shaped subvisible particles (AR \(\geq 0.85\), regarded as oil droplets) was detected in the SO system (average 963/mL), whereas much less or even a negligible amount was found in the SOF system (2/mL), suggesting that the proposed SOF system contributes a significantly smaller number (\(p < 0.001\), \(n = 10\)) of subvisible particles than the SO system. It is known that subvisible particles could be formed by the ingress of SO to the medium from the siliconized plunger stopper or barrel\(^{6,11,12}\). The observed phenomenon, therefore, may be caused by the same reason. When protein formulation was filled in syringes (Asp sol.), the number of subvisible particles (AR \(\geq 0.85\)) drastically increased in the SO system (average 12,099/mL), whereas almost no change was observed in the SOF system.
Figure 3. Comparison of the numbers of subvisible particles generated after filling water for injection (water), model protein solutions such as asparaginase (Asp sol.), human IgG sol., bovine serum albumin (BSA sol.), and lysozyme (Lyso sol.) into the SO and the SOF system, determined by MFI analysis. (a) AR \( < 0.85 \), (b) AR \( < 0.85 \). Data represent the mean values and corresponding standard deviations \( (n = 10 \) for water, \( n = 5 \) for model proteins).

system (average 73/mL), suggesting that the protein solution may accelerate the ingress of SO by some interfacial interaction or, that the ingressed oil subsequently forms protein–silicone–oil aggregates \( (p < 0.05, n = 5) \). The same tendencies were also observed in other model proteins (IgG sol., BSA sol., and Lyso sol.).

Figure 3b presents a comparison of the measurement result for noncircular-shaped particles (AR \( < 0.85 \), regarded as protein aggregates) between the SO and the SOF system. Analogous results were obtained in the two cases of water-filled and protein-solution-filled syringes (Asp sol.). Namely, when the SO system was used for protein formulation, an extremely large number of particles was formed (average 46,659/mL), whereas significantly fewer were generated in the SOF system (average 897/mL) \( (p < 0.05, n = 5) \). From the results of a previous study, BSA was believed to be a positive control as it showed the most dramatic SO-induced aggregation at pH 7.2. On the other hand, Lyso was expected to be a negative control as no particular change was observed at pH 7.2. Because of the large error bar, we cannot discuss all of the details of this result. However, BSA showed a SO-induced aggregation even though the \( t \) value was \( >0.05 \) \( (p \) value was 0.051 in case of AR \( < 0.85 \)) and Lyso showed a lesser impact of SO \( (p \) value was 0.40 in case of AR \( < 0.85 \)). In the Lyso sample, relatively higher particle counts were observed even in the SOF system. To obtain further information, an additional study was conducted with noncoated plunger stopper and syringe. As a result, after shaking samples, the particle counts increased even in the non-SO condition (data not shown). This result suggests that the high particle counts were not caused by SO but rather physical stress itself. Overall, the same tendencies were observed in all model proteins. Therefore, we assume that it can be minimized through a reduction in the content of SO in protein pharmaceutical formulations. It is interesting that a large number of circular particles (AR \( \geq 0.85 \)) was observed in the water filled SO system (average 963/mL), whereas the number of noncircular particles (AR \( < 0.85 \)) was quite small (average 2/mL).

The observed decrease also suggests that SO droplets could have the potential to induce protein aggregation in the various protein solutions.

Although the detailed mechanism of the formation of protein aggregations is still obscure, all the results clearly prove that SO causes the formation of subvisible particles and, hence, that the SOF system based on the i-coating™ technology is superior to the SO system in terms of avoiding the formation of subvisible particles in the syringe.

Container Closure Integrity

The CCI of the SOF system was tested by dye and microbial penetration studies. Figure 4 schematically shows the configuration of the sample syringe used for this study, and the results of the dye penetration test using 1% crystal violet as marker. The syringes with various headspaces were tested to examine the influence of internal pressure. As listed in the table, all samples showed very low absorbance (lower than the detection limit), irrespective of the volume of the headspace, meaning that the penetrated dye amount was almost negligible. Actually, the calculated concentration of crystal violet in the inner, water-filled volume was less than \( 10^{-5} \) times that of the outer solution. This result assures a sufficient CCI of the SOF system.

The results of a microorganism penetration study are shown in Figure 5. After 14 days of incubation, the TSB culture medium, filled in the SOF syringes and immersed in a bacterial

Yoshino et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:1520–1528, 2014 DOI 10.1002/jps.23945
broth ($10^6$ cfu/mL), did not show any particular changes in its appearance and the solution inside of the syringes remained clear (Fig. 5a). By contrast, pin-holed SOF syringes (positive control) showed a considerable change in that the medium became turbid (Fig. 5b).

The judgments for the occurrence of microbial growth were 0/4 for the SOF syringe and 5/5 for its positive control. This result indicates that the SOF system did not allow the penetration of microorganisms.

**Dynamic Friction-Coefficient Analysis**

In order to assess quantitatively the lubricious properties of coated plunger stoppers, the dynamic friction coefficient was determined using a continuous-loading surface property tester. Butyl rubber sheets, pristine, coated by SO and coated by the i-coating™ technology, were used as model samples replacing the plunger stoppers used in the SO and the SOF system, respectively, because of their identical surface composition.

Figure 6 presents the comparison of the dynamic friction coefficients determined for the three materials investigated: uncoated butyl rubber sheet, SO-coated butyl rubber sheet, and coated butyl rubber sheet. The purpose of this study was to measure the smoothness of the solid surface property. As evident from Figure 6, the dynamic friction coefficient of the coated butyl rubber sheet was 10 times lower than that of the uncoated butyl rubber sheet ($p < 0.001$, $n = 9$). Observation using SEM (Fig. 1) revealed that the surface of the coated plunger stopper was much smoother than that of the uncoated one. Therefore, it is assumed that the obtained result clearly showed the degree of surface smoothness between uncoated butyl rubber and the sheet coated using the i-coating™ technology.
Surprisingly, it is notable that the dynamic friction coefficient of the sheet coated using the i-coating™ technology was lower than that of the SO-coated butyl rubber sheet \((p < 0.001, n = 9)\). As mentioned above, this study measured the smoothness of the solid surface property. However, according to a fluid lubricant coating such as SO, it would be difficult to predict the difference between coated butyl rubber sheets with solid lubrication and that of the SO-coated butyl rubber sheet with fluid lubrication as the SO on the surface is easily moved when force is applied. In this measurement, a steel ball was placed vertically on the sheet surface and pulled back horizontally to measure the surface friction. However, in cases of plunger stopper movement within the syringe, a concentric force was generated by the plunger stopper expansion.

Among those differences, it is thought these conclusions have been obtained only by comparing the material physical properties, that is, the apparent dynamic friction coefficients, of the samples. They may not be completely representative of the findings obtained using actual plunger stoppers. Although the value of this study is the ability to simply obtain differences as quantitative values, these results strongly indicate that the application of i-coating™ to a butyl rubber surface drastically decreases the friction resistance of the surface without using SO.

**Gliding Force Measurement**

A comparative study was conducted to reveal the difference in the gliding force between the SO and the SOF system. To simulate the condition under which syringes are actually used, the specimens were stored at 40°C for 12 weeks in advance. The profiles of the gliding force of the SO and the SOF system are shown in Figure 7.

As seen in Figure 7, both syringe systems provided different gliding force profiles. The SO system showed a maximum gliding force of 9 N in the form of a sharp peak at a stroke distance of 3 mm (break loose). The gliding force subsequently reduced to a lower level of about 2 N. On the contrary, no significant difference between the break loose and gliding force was observed in the SOF system. After the initial rise to about 3 N, the gliding force gradually increased to the maximum value of 6 N at a stroke distance of 30 mm.

The observed difference in the gliding force profile is thought to originate from the difference in the lubrication mechanism of both syringe systems. Namely, in the SO system, as SO is coated onto the surfaces of the barrel and the plunger stopper, the SO on the barrel always provides additional lubricity while the plunger stopper moves down in the barrel. Therefore, the gliding force under steady-state conditions is lower compared with the SOF system. In this case, however, because sufficient SO cannot be supplied at the initial stage, a large gliding force is required as a break loose force until the plunger stopper starts to move. This type of profile is commonly observed in currently available SO system including disposable types of syringes.

On the other hand, the SOF system has a lubricious silicone-based resin that is coated on the plunger stopper instead of SO. Even though the gliding force of the SOF system was a little higher than in the SO system, it is far below the maximum permissible value for actual use. This could be caused by the absence of additional lubricity in the SOF syringes, supplied by SO in the SO system, to reduce the friction force generated during the movement of the plunger stopper. To confirm this, the actual moving plunger stopper shape was observed using a CCD camera. As a result, it was observed that the distance of the two ribs decreased and the width of plunger stopper (between two ribs) increased (data not shown). This indicates that the plunger stopper was compressed and the expansion force increased before the plunger stopper moved. This conclusion is also supported by the observed gradual increase in the gliding force.

In order to examine further differences in the break loose force between the SO and the SOF system, stability studies were performed at 4°C, 25°C, and 40°C for 24 weeks. In this study, the maximum force between 0 and 5 mm of stroke
distance was defined as “break loose force.” The results are shown in Figures 8a and 8b.

As seen in Figure 8a, the break loose forces in the SO system gradually increased with the lapse of time and finally reached constant equilibrium values after 8 weeks. These constant values increased on increasing temperature (about 6 N at 5°C, 8 N at 25°C, and 10 N at 40°C). On the other hand, as seen in Figure 8b, no changes were observed in the break loose force of the SOF system, irrespective of storage period and temperature. The constant break loose force value was about 3 N in all investigated cases.

The temperature dependence of the break loose force observed in the SO system could be attributed to the thermal expansion of the plunger stopper. For more details, it is considered that the SO layer located between plunger stopper and barrel is gradually spread out in response to the plunger stopper expansion on aging time, resulting in a thinner SO layer that increases the initial friction (break loose force). The viscosity of the SO may contribute to the observed temperature dependence in various ways. On the other hand, in case of the SOF syringe, in which the plunger stopper is coated chemically with a silicone-based resin, the lubricity of the plunger stopper hardly changes by temperature or aging time, as evidenced by Figure 8b.

CONCLUSIONS

Through a series of comparative studies, it was demonstrated that a newly developed SOF system prevents effectively the formation of subvisible particles including both, SO droplets and oil-induced aggregations. Furthermore, it was confirmed by dye and microorganism penetration studies that the SOF system assures a sufficient CCI. In addition, the SOF system showed no significant difference between the break loose and gliding force and did not change with aging time and temperature. Therefore, the SOF syringes enable to minimize the risk of unexpected rapid release during aspiration and unexpected gliding force change during storage. All these results prove that the newly developed SOF system using the i-coating™ technology has great advantages compared with the current SO system.

In conclusion, the proposed novel SOF system has a great potential and represents a novel alternative that can achieve a very low level of subvisible particles, secure CCI, and the absence of a break loose force. In particular, no risk of SO-induced aggregation and very low level of subvisible particles can bring additional value to the highly sensitive biotech drug market.

REFERENCES

1. Chantelau E. 1989. Silicone oil contamination of insulin. Diabet Med 6(3):278.
2. Chantelau E, Berger M, Böhlken B. 1986. Silicone oil released from disposable insulin syringes. Diabetes Care 9(6):672–673.
3. Baldwin RN. 1988. Contamination of insulin by silicone oil: A potential hazard of plastic insulin syringes. Diabet Med 5(8):789–790.
4. Collier FC, Dawson AD. 1985. Insulin syringes and silicone oil. Lancet 2:611.
5. Bernstein RK. 1987. Clouding and deactivation of clear (regular) human insulin: Association with silicone oil from disposable syringes?. Diabetes Care 10:786–787.
6. Jones LS, Kaufmann A, Middaugh CR. 2005. Silicone oil induced aggregation of proteins. J Pharm Sci 94(4):918–927.
7. Thirumangalathu R, Krishnan S, Ricci MS, Brems DN, Randolph TW, Carpenter JF. 2009. Silicone oil and agitation-induced aggregation of monoclonal antibody in aqueous solution. J Pharm Sci 98(9):3167–3181.
8. Gerhardt A, Bonam K, Bee JS, Carpenter JF, Randolph TW. 2013. Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil–water interfaces. J Pharm Sci 102(2):429–440.
9. Li J, Pinnamaneni S, Quan Y, Jaiswal A, Andersson FI, Zhang X. 2012. Mechanistic understanding of protein-silicone oil interactions. Pharm Res 29(6):1689–1697.
10. Dixit N, Maloney KM, Kalonia DS. 2012. The effect of Tween® 20 on silicone oil–fusion protein interactions. Int J Pharm 429(1–2):158–167.
11. Mahler HC, Friess W, Gauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98(9):2909–2934.

DOI 10.1002/jps.23945
Yoshino et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:1520–1528, 2014
12. Wang W, Nema S, Teagarden D. 2010. Protein aggregation—pathways and influencing factors. Int J Pharm 390(2): 89–99.
13. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause HJ, Meyer BK, Narhi L, Nesta DP, Spitznagel T. 2010. An industry prospective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 99(8):3302–3321.
14. Ripple DC, Dimitrova MN. 2012. Protein particles: What we know and what we do not know. J Pharm Sci 101(10):3568–3579.
15. Bee JS, Goletz TJ, Ragheb JA. 2012. The future of protein characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: A shared perspective. J Pharm Sci 101(10):3580–3585.
16. Majumdar S, Ford BM, Mar KD, Sullivan VJ, Ulrich RG, D’souza AJM. 2011. Evaluation of the effect of syringe surfaces on protein formulations. J Pharm Sci 100(7):2563–2573.
17. Huang CT, Sharma D, Oma P, Krishnamurthy R. 2009. Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci 98(9):3058–3071.
18. Sharma D, Oma P, King D. 2009. Applying intelligent flow microscopy to biotechnology. Bioprocess Int 7(6):62–67.
19. Pharmaceutical inspection convention (pharmaceutical inspection co-operation scheme, PI 007–6, 1 January 2011: Recommendation on the validation of aseptic processes, 9. Important factors in validation of aseptic manufacturing, 9.1 Container/Closure Integrity Testing).
20. Badkar A, Wolf A, Bohack L, Kolhe P. 2011. Development of biotechnology products in pre-filled syringes: Technical considerations and approaches. AAPS PharmSciTech 12(2):564–572.
21. Wen ZQ, Vance A, Vega F, Cao X, Eu B. 2009. Distribution of silicone oil in prefilled glass syringes probed with optical and spectroscopic methods. PDA J Pharm Sci Technol 63(2):149–158.